Prevention of cardiovascular disease: an evidence-based clinical aid 2004

Fulcher, Greg R; Conner, Greg W; Amerena, John V

doi:10.5694/j.1326-5377.2004.tb06317.x

Topics

Cardiovascular disease is the leading cause of morbidity and mortality in Australia. It is therefore important that all medical practitioners are familiar with the well documented risk factors for cardiovascular disease, as well as the outcome benefits of pharmacological and other interventions.

Department of Diabetes, Endocrinology and Metabolism, Royal North Shore Hospital, St Leonards, NSW.
1 Cardiovascular Diagnostic Services, Liverpool, NSW.
2 Geelong Hospital, and Department of Clinical and Biomedical Sciences, University of Melbourne, Melbourne, VIC.

Correspondence: gfulcher@med.usyd.edu.au

Acknowledgements:

The taskforce steering committee would like to acknowledge the contributions of the writing committee: Dr Greg R Fulcher, Dr John V Amarena, Dr Greg W Conner, Professor Richard E Gilbert and Professor Graeme J Hankey.

Competing interests:

A summary of the competing interests of the members of the Practical Implementation Task Force is given in Box 2.

1. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
2. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
3. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
4. Royal College of Physicians. Smoking and health now. London: Pitman Medical and Scientific, 1971.
5. US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General. DHHS Publication (CDC) 90-8416. Rockville, Md: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, 1990.
6. Eaton C. Relation of physical activity and cardiovascular fitness to coronary heart disease. Part II: cardiovascular fitness and the safety and efficacy of physical activity prescription. J Am Board Fam Pract 1992; 5: 157-165.
7. Sacco R, Gan R, Boden-Albala B. Leisure-time physical activity and ischaemic stroke risk: the Northern Manhattan stroke study. Stroke 1998; 29: 380-387.
8. Berlin J, Colditz G. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 1990; 132: 612-628.
9. Oldridge N, Guyatt G, Fischer M, Rimm A. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA 1988; 260: 945-950.
10. O’Connor G, Buring J, Yusuf S, et al. An overview of randomised trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 80: 234-244.
11. Joshipura K, Manson J, Stampfer M, et al. The effect of fruit and vegetable intake on risk for coronary heart disease. Ann Intern Med 2001; 134: 1106-1114.
12. De Lorgeril M, Salen P, Martin J, et al. Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779-785.
13. Daviglus M, Stamler J, Orencia A, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 1997; 36: 1046-1053.
14. Leren P. The Oslo diet-heart study — 11 year report. Circulation 1970; 42: 935-942.
15. Bunker S, Colquhoun D, Esler M, et al. “Stress” and coronary heart disease: psychosocial risk factors. National Heart Foundation of Australia position statement update. Med J Aust 2003; 178: 272-276. <MJA full text>
16. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
17. PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24: 475-484.
18. Yusuf S, Peto R, Lewis J, et al. Beta-blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 1985; 27: 335-371.
19. Acute Infarction Ramipril Efficacy (AIRE) Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
20. Opie L, Yusuf S, Kubler W. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. Prog Cardiovasc Dis 2000; 43: 171-196.
21. Danish Study Group on verapamil in myocardial infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II – DAVIT II). Am J Cardiol 1990; 66: 779-785.
22. Multicentre Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385-392.
23. Flack J, Neaton J, Grimm R Jr, et al. Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation 1995; 92: 2437-2445.
24. Lenfant C, Chobanian A, Jones D, et al. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension 2003; 41: 1178-1179.
25. National Heart Foundation. Hypertension management guide for doctors 2004. Canberra: NHF, 2003. Available at: www.heartfoundation.com.au/index.cfm?page=36 (accessed May 2004).
26. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular mortality in hypertension: the Nordic diltiazem (NORDIL) study. Lancet 2000; 356: 359-365.
27. Staessen J, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757-764.
28. HANE Trial Research Group. Randomised, double-blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. BMJ 1997; 315: 154-159.
29. Staessen J, Gasowski J, Wang J, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865-872.
30. Psaty B, Smith N, Siscovick D, et al. Health outcomes associated with antihypertensive therapies used as first line agents: a systematic review and meta-analysis. JAMA 1997; 277: 739-745.
31. Messerli F, Grossman E, Goldbourt U. Are beta-blockers efficacious as first line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903-1907.
32. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97-104.
33. Dahlof B, Lindholm L, Hansson L, et al. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-hypertension). Lancet 1991; 338: 1281-1285.
34. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
35. Hansson L, Lindholm L, Niskanen L, et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999; 353: 611-616.
36. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Effect of antihypertensive treatment in patients having already suffered from stroke: gathering the evidence. Stroke 1997; 28: 2557-2562.
37. Rodgers A, Neal B, McMahon S. The effects of blood pressure lowering in cerebrovascular disease. Neurol Rev Int 1997; 2: 12-15.
38. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
39. Pepine C, Handberg E, Cooper-DeHoff R, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil–Trandolapril Study (INVEST): a randomised controlled trial. JAMA 2003; 290: 2805-2816.
40. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
41. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
42. Sacks F, Pfeffer M, Moye L, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001-1009.
43. Cannon C, Brauwald E, McCabe C, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
44. Rubins H, Robins S, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418.
45. Pedersen T, Berg K, Cook T, et al. Safety and tolerability of cholesterol lowering with simvastatin during five years in the Scandinavian Simvastatin Survival Study (4S). Arch Intern Med 1996; 156: 2085-2092.
46. Wood D, de Backer G, Faergeman O, et al. Clinicians’ manual on total risk management. In: Davenport L, ed. A guide to prevention of coronary heart disease. London: Science Press, 2000.
47. Fuller J, Stevens L, Chaturvedi N, Holloway J. Antihypertensive therapy for preventing cardiovascular complications in people with diabetes. Cochrane Database Syst Rev 2003; (1): CD002188.
48. Estacio R, Jeffers B, Hiatt W, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652.
49. Tatti P, Pahor M, Byington R, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.
50. Agodoa L, Appel L, Bakris G, et al. African American study of kidney disease and hypertension (AASK) study group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomised controlled trial. JAMA 2001; 285: 2719-2728.
51. Bakris G, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661.
52. Lewis E, Hunsicker L, Clarke W, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
53. Parving H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
54. Brenner B, Cooper M, de Zeeuw D, et al. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
55. Lindholm L, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
56. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
57. Downs J, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
58. Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-825.
59. Elkeles R, Diamond J, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998; 21: 641-648.
60. Keirnan E, Keech A. FIELD. Sydney: National Health and Medical Research Council Clinical Trials Centre, September 2003. Information available at: www.ctc.usyd.edu.au/trials/cardiovascular/field.htm (accessed May 2004).
61. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
62. Mann J, Gerstein H, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636.
63. Giatras I, Lau J, Levey A. Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997; 127: 337-345.
64. Hillege H, van Gilst W, van Velduisen D, et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomised trial. Eur Heart J 2003; 24: 412-420.
65. Nakao N, Yoshimura A, Morita J, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124.
66. Smith S Jr, Greenland P, Grundy S. Beyond secondary prevention: identifying the high-risk patient for primary prevention: executive summary. AHA Conference Proceedings. Prevention conference V. American Heart Association; Circulation 2000; 101: 111-116.
67. Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Hum Hypertens 1996; 10: 1-8.
68. Hansson L, Lindholm L, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756.
69. Appel L. The verdict from ALLHAT – thiazide diuretics are the preferred initial therapy for hypertension. JAMA 2002; 288: 3039-3042.
70. Katerndahl D, Lawler W. Variability in meta-analytic results concerning the value of cholesterol reduction in coronary heart disease: a meta-meta-analysis. Am J Epidemiol 1999; 149: 429-441.
71. Shepherd J, Cobbe S, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
72. LaRosa J, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-2346.
73. Sever P, Dahlöf B, Poulter N, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
74. National Heart Foundation of Australia and The Cardiac Society of Australia and New Zealand. Lipid management guidelines – 2001. Med J Aust 2001; 175 (9 Suppl): S57-S88.
75. Wing L, Reid C, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592.
76. New Zealand Guidelines Group. The assessment and management of cardiovascular risk. Wellington: New Zealand Guidelines Group, December 2003. Available at: www.nzgg.org.nz/guidelines/0035/CVD_Risk_Full.pdf (accessed Jun 2004).
77. Lovell H. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microlbuminuria. Cochrane Database Syst Rev 2000; (2): CD002183.
78. Hung J, Medical Issues Committee of the National Heart Foundation of Australia. Aspirin for cardiovascular disease prevention. Med J Aust 2003; 179: 147-152. <MJA full text>
79. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2004; 27 (Suppl 1): S72-S73.
80. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
81. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002; 324: 71-86.
82. Hansson L, Zanchetti A, Carruthers S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
83. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2000; 23 (Suppl 1): S61-S62.
84. Diener H, Cunha L, Forbes C, et al. European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
85. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
86. Wilterdink J, Easton J. Dipyridamole plus aspirin in cerebrovascular disease. Arch Neurol 1999; 56: 1087-1092.
87. De Shryver E, ESPRIT Study Group. Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. Stroke 2003; 34: 2339-2342.
88. Yusuf S, Zhao F, Mehta S, et al. Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
89. Steinhubl S, Berger P, Mann J 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420.
90. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with non-rheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333: 5-10.
91. Llach F. Hypercoagulability, renal vein thrombosis and other thrombotic complications of the nephrotic syndrome. Kidney Int 1985; 28: 429-439.

Online responses are no longer available. Please refer to our instructions for authors page for more information.